Bull & Bear

Bull and Bear

Verdict: Avoid — the bear's evidence is printed; the bull's is optionality. At $8.93 the equity is roughly cash-backed, but the trajectory underneath that cash is hostile: Q1 FY26 revenue collapsed 49% YoY to $19.5M (worst since Q3 FY20), management withdrew FY26 revenue guidance, and founders sold ~$13M into a 52-week-low cluster ten weeks after FY25 mega-grants vested. The cash "floor" is gross — net of the $417M 2027 convertible and a $606M post-2026 non-cancellable lease wall against $170M of revenue, the margin of safety thins. The decisive tension is whether Cell Engineering re-bases above $30M/quarter in Q2 FY26 (August 2026); below $25M and consensus likely resets toward a $130M FY26 trajectory, putting the 2027 convert into refinancing conversations from weakness. Own the optionality after a named top-10 pharma signs a multi-RAC commercial contract — not before.

Bull Case

Bull's scenario target is $14 on a 12–18 month horizon. Method: sum-of-parts — $422M cash + securities = $7.10/share floor, plus a 5x EV/revenue multiple on a stabilized $170M revenue base discounted 30% for execution risk and ~9% dilution drag. The primary catalyst window is Q2 or Q3 FY26 earnings (August–November 2026), where the bull would expect Datapoints broken out as a separately disclosed revenue line growing >50% YoY with a named top-10 pharma anchor. The disconfirming signal is a Q2 FY26 Cell Engineering print below $25M (second consecutive sub-$30M quarter) or FY26 burn re-accelerating above the $150M high end of guide.

Bear Case

Bear's downside scenario is $3.50 (~61% below current $8.93) on a 12–18 month horizon. Method: peer-floor multiple compression of 1.5x P/S on a post-divestiture FY26 revenue base of $130–150M, plus residual net cash of ~$100M after another $171M of FY26 burn and a partially-dilutive 2027 convertible refinancing that takes diluted share count from 59.6M to ~75M. Implied equity ≈ $260–280M ÷ ~75M shares ≈ $3.50. The primary trigger is Q2 FY26 earnings (August 2026) if Cell Engineering revenue prints below $25M versus the implicit ~$40M needed to defend FY26 cash-burn math. The cover signal is a named top-10 pharma anchor publicly committing to a multi-RAC autonomous-lab deployment at commercial pricing (not pilot, not government), or the 2027 convertibles refinanced at par with a sub-6% coupon and no equity-exchange component.

The Real Debate

Verdict

Verdict: Avoid. The bear carries more weight because its evidence is printed numbers — a 49% YoY revenue collapse to a five-year low, withdrawn guidance, a quietly-dropped EBITDA breakeven target, $13M of insider sales into a 52-week low ten weeks after mega-grants vested — while the bull's case rests on optionality that has not yet shown up in reported revenue. The decisive question is whether Q1 FY26's $19.5M is a noisy print or a trajectory; if Cell Engineering does not re-base above $30M/quarter in Q2 FY26, the implicit FY26 cash-math snap-back fails and the 2027 convertible refinancing is negotiated against a $606M lease wall. The bull could still be right: at $8.93 the operating business is priced near zero against $422M of gross cash, and a named top-10 pharma multi-RAC commercial deployment would mark a category validation no peer is positioned to absorb. The verdict flips to Lean Long, Wait For Confirmation on either of two observable conditions — a Q2 FY26 Cell Engineering print at or above $30M with a named top-10 pharma anchor disclosed, or a 2027 convertible refinancing at par with sub-6% coupon and no equity-exchange component. Until then, the cash floor protects against ruin but does not justify owning a business whose own management has stopped guiding revenue and whose founders are selling at five-year lows.